Pharma C Investments CEO Chana Greenberg joins Proactive London’s Katie Pilbeam to discuss the company’s plans to list in the British capital.
Greenberg says there is a ‘massive amount of excitement and momentum around medicinal cannabis as more and more companies list and show this is a regulated medical market, a good quality pharmaceutical product for targeted medical conditions and we’ve seen some phenomenal valuations recently’.
The investment vehicle is set up to identify and pursue opportunities and acquisitions in companies to specifically take advantage of the burgeoning commercial and dynamic regulatory environment surrounding legal medicinal cannabis.
Read More: Pharma C Investments on AQUIS listing ‘targeting break out firms and winners’ in